The impact of subclinical hypothyroidism on long-term outcomes in older patients undergoing percutaneous coronary intervention

Table 4 Relative risks for cardiac death in patients with SCH vs. ET

	Death(n)	Number at risk(n)	Unadjusted RR	95%CI	P Value	Adjusted RR	95%CI	P Value
ET	108	2848	1.000 (reference)			1.000 (reference)
SCH	16	320	1.326	0.785–2.242	0.292	1.231	0.650–2.334	0.524
Age<75 years
ET	83	2276	1.000			1.000
SCH	14	268	1.445	0.820–2.545	0.203	1.304	0.639–2.661	0.467
Age ≥ 75 years
ET	25	572	1.000			1.000
SCH	2	52	0.876	0.208–3.700	0.858	0.762	0.324–1.678	0.938
Male
ET	73	1696	1.000			1.000
SCH	7	132	1.225	0.564–2.661	0.607	0.917	0.351–2.397	0.860
Female
ET	35	1152	1.000			1.000
SCH	9	186	1.602	0.770–3.333	0.207	1.0000	0.348–2.870	1.000
TSH
0.34–5.60	108	2848	1.000			1.000
5.61–9.99	13	278	1.238	0.696–2.201	0.467	1.054	0.508–2.187	0.887
≥10	3	42	1.934	0.614–6.092	0.260	1.321	0.274–6.358	0.729

Adjusted RR: adjusted for age, gender, body mass index, hypertension, diabetes mellitus, hyperlipidemia, smoking, family history of coronary artery disease, History of myocardial infarction, history of percutaneous coronary intervention, history of coronary artery bypass graft, history of stroke, history of heart failure, History of renal failure, acute myocardial infarction, left ventricle ejection fraction, hemoglobin, fasting glucose, creatinine, total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, high-sensitivity C-reactive protein, aspirin, clopidogrel, ß-Blocker, angiotensin II coenzyme inhibitor, angiotensin II receptor blocker, statins, multi-vessel disease, left main, left anterior descending, left circumflex artery, right coronary artery

ISSN: 1472-6823